{
  "docId": "019de076-7d6c-774e-85e8-ffe50da37251",
  "docSlug": "0b0d701714d17efa78c23c196990e90c",
  "documentTitle": "Genelux | Investor Presentation Deck | 37 slides",
  "authorId": "genelux",
  "authorName": "Genelux",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-12-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 14,
  "pageCount": 37,
  "prevPage": 13,
  "nextPage": 15,
  "slideType": "traction",
  "function": "show_traction",
  "density": "dense",
  "nDataPoints": 12,
  "notes": "Includes a Kaplan-Meier plot with a table comparing historical data to VIRO-15 trial results.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de076-7d6c-774e-85e8-ffe50da37251/14",
  "deckHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251",
  "deckJsonHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251.json",
  "deckAnchorHref": "/decks/019de076-7d6c-774e-85e8-ffe50da37251#slide-14",
  "components": [
    {
      "bbox": {
        "h": 0.65,
        "w": 0.28,
        "x": 0.04,
        "y": 0.18
      },
      "kind": "callout",
      "text": "Key Clinical Takeaways\n\nEncouraging mOS and Long-term survival data\n\n20% long-term survivors consistent with commercially successful immunotherapies\nOn a median 5th line of treatment, VIRO-15 Phase 2 patients achieved a mOS of 15.7 mos\n4 of 6 long-term survivors were platinum-refractory at enrollment",
      "attrs": null,
      "subkind": "primary",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d064b127-eb68-4a03-ab20-66742191d1d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.55,
        "x": 0.38,
        "y": 0.2
      },
      "kind": "chart",
      "text": "Kaplan-Meier survival curve",
      "attrs": null,
      "subkind": "line",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f481f7ad-5de9-43be-a567-1bf56684268c",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.35,
        "x": 0.6,
        "y": 0.3
      },
      "kind": "source-note",
      "text": "1Bookman et al., Gynecol Oncol. 2017;146(1):58-63\n2SORAYA P3 Trial Result; SGO Annual Mtg, Mar 2023",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2a8de7a1-b748-4eec-a14c-a99fcda53a83",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.35,
        "x": 0.6,
        "y": 0.35
      },
      "kind": "table",
      "text": "Meaningful Clinical Benefit in Heavily Pre-treated Patients VIRO-15",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0a6b3bf5-80ab-4e48-849d-241c1bb63361",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.35,
        "x": 0.6,
        "y": 0.12
      },
      "kind": "table",
      "text": "Prognosis Worsens with each Successive Line",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b609ba7b-d64f-4924-9ded-6dc13bb74294",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.03,
        "y": 0.03
      },
      "kind": "title",
      "text": "Durable Survival Benefit",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e888fc2e-2f18-40a0-8aaf-8c53ec4b543e",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "8ba596cf-4e04-46da-9b90-1a7d3e7c162b",
      "evidence": "table/data: Meaningful Clinical Benefit in Heavily Pre-treated Patients VIRO-15",
      "confidence": 0.8
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 14,
      "from": 9,
      "beatId": "83a3aa16-5d5b-40f0-bd18-2beeecaa8bff",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Traction",
      "beatSlug": null,
      "evidence": "The traction section highlights the results of phase 1b trials and the potential of Olvi-Vec.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}